Compare Amylx Pharmaceuticals Inc (AMLX) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Petróleo Brasileiro SA — how do they compare? Amylx Pharmaceuticals Inc trades at $17.34 (market cap $1.98B), while Petróleo Brasileiro SA trades at $17.61 (market cap $105.14B). The key difference: Petróleo Brasileiro SA is far larger — about 53.1× Amylx Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 10.18% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PBR | |
|---|---|---|
Market Cap | $1.98B | $105.14B |
Sector | Health | Technology |
52-Week High | $18.70 | $22.03 |
52-Week Low | $7.64 | $11.54 |
Enterprise Value | $1.70B | $167.68B |
Dividend Yield | — | 10.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Petrobras (PBR) trades at $17.32, up 1.7% with bullish technical signals and strong fundamentals. The stock shows attractive valuation metrics with P/E of 5.52 and ROE of 24.94%, supported by robust cash flow generation of $197.5B in 2025. Recent developments include strategic partnerships with Pemex and renewable energy investments, while maintaining consistent dividend payments.
PBR presents compelling value with significant upside to the $23.90 consensus target, though faces risks from commodity volatility and recent earnings miss. The company's production growth and cost discipline support long-term investment case, but investors should monitor execution on new projects and oil price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
